Mechanism of Action: Multi-Step Blockade
Structurally, the drug is an abnormal nucleoside. Ribavirin acts as a classical prodrug: it is inactive on its own and requires mandatory intracellular phosphorylation. This process is carried out by cellular kinases that sequentially convert the molecule into mono-, di-, and triphosphate forms.
The antiviral mechanism operates in two main stages:
- Effects of ribavirin monophosphate: At this stage, the drug acts as a competitive inhibitor of a crucial enzyme, inosine monophosphate dehydrogenase. Blockade of this enzyme leads to a sharp drop in intracellular guanosine triphosphate (GTP) levels. GTP depletion makes full synthesis of viral nucleic acids impossible.
- Effects of ribavirin triphosphate: Accumulating as a triphosphate, the drug directly inhibits viral RNA polymerase. This completely blocks the synthesis of viral messenger RNA (mRNA).
An important feature of this mechanism is its high selectivity. The drug is lethal to viruses while having minimal impact on RNA synthesis processes in healthy human cells.
Clinical Application and Routes of Administration
The spectrum of activity is extremely broad. Historically, it was used against influenza A and B, herpesviruses, measles, and adenoviruses. However, due to toxicity, it is rarely used for these infections today, being reserved only for the most severe clinical cases.
Modern indications are strictly differentiated according to the route of administration:
- Oral administration: For many years, the drug was a backbone in the treatment of chronic hepatitis C. A crucial condition for its efficacy is its use strictly in combination with interferon-alpha preparations. Ribavirin monotherapy for hepatitis C is considered insufficiently effective. Intestinal absorption occurs via active transport through specific nucleoside transporters (trade names for oral forms include Rebetol, Ribavirin).
- Inhalation (aerosol): Used in pediatric practice to treat severe bronchiolitis and pneumonia in children caused by respiratory syncytial virus (RSV).
- Intravenous administration: Vital in treating highly hazardous viral infections, such as hemorrhagic fever with renal syndrome, Crimean-Congo hemorrhagic fever, and Lassa fever.
Additionally, in patients with severe immunosuppression, combination therapy including ribavirin and intravenous immunoglobulin is practiced.
Safety Profile and Adverse Effects
The drug's safety profile requires close medical attention, as adverse effects directly depend on the route of administration:
- Systemic action (oral intake): Pronounced hematotoxicity comes to the forefront, manifesting as anemia, neutropenia, and thrombocytopenia. Cardiovascular side effects may include bradycardia, while central nervous system effects can include persistent insomnia.
- Inhalation use: Local reactions occur. Patients may experience irritation of the respiratory tract mucosa, wheezing, and an objective drop in pulmonary function parameters.
- Preclinical data: Laboratory studies have revealed oncogenic potential. Furthermore, its teratogenic and embryotoxic effects are well-documented, making its use extremely hazardous during pregnancy.